MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fneur.2026.1827022

Медицинская библиотека · Frontiers in neurology · 2026

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan.

Kasai Hideyo, Yasumoto Taro, Kosuge Shota, Osanai Ayako, Mizuma Keita, Futamura Akinori, Kuroda Takeshi, Ono Kenjiro, Murakami Hidetomo

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Long-term real-world evidence beyond 24 months for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies is scarce, particularly regarding treatment persistence and planned discontinuation after goal attainment.

METHODS

We conducted a single-center retrospective study of consecutive patients aged ≥15 years who initiated galcanezumab or fremanezumab (monthly/quarterly) between May 2021 and June 2022. Specifically, patients aged ≥15 years with episodic migraine (EM; <15 headache days/month), high-frequency EM (HFEM; 8-14 days/month), or chronic migraine (CM; ≥15 days/month) were included according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. The outcomes included monthly migraine days (MMDs), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test (HIT-6), and the Visual Analogue Scale (VAS), which were assessed at baseline and at 1, 3, 6, 12, and 36 months. Responder rates (RRs) (≥50%, ≥75, and 100%) and continuation/discontinuation reasons were summarized with prespecified and sensitivity analyses. The primary subgroup analysis was prespecified as EM vs. HFEM+CM.

RESULTS

Overall, 50 patients were analyzed at baseline (mean age: 42.5 years; 88% women); 28 of the 50 (56%) patients continued therapy for 3 years. Among patients who continued therapy, MMDs decreased from 12.0 ± 5.4 to 5.6 ± 5.4 at 36 months, with parallel improvements in the MIDAS, HIT-6, and VAS (all p < 0.01). Responder rates were durable (≥50%: 55.6% at 36 months; ≥75%: 29.6%; 100%: 11.1%). Discontinuation frequently reflected treatment completion after goal attainment (24%); no adverse-event-related discontinuations occurred.

CONCLUSION

Over 3 years, anti-CGRP monoclonal antibodies provided sustained preventive effectiveness and favorable tolerability in routine practice, supporting individualized decision-making regarding continuation, planned discontinuation, and regimen selection.

Для цитирования: Kasai Hideyo, Yasumoto Taro, Kosuge Shota, Osanai Ayako, Mizuma Keita, Futamura Akinori, Kuroda Takeshi, Ono Kenjiro, Murakami Hidetomo. Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan.. Frontiers in neurology. 2026. DOI: 10.3389/fneur.2026.1827022.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.